Friday, December 24, 2010

Exercise of Full OverAllotment Option for Total Net Proceeds of US 43 M, YM BioSciences YMI

The Company intends to use the proceeds to fund its drug development activities and for general corporate purposes. The securities described above were offered and sold by the Company pursuant to a registration statement filed with the Securities and Exchange Commission (SEC), which became effective on December 1, 2010.


Thursday, December 23, 2010

XSNX Soalr Stock News XsunX Produces CIGSolar Cell Devices That Surpass, 14 Percent Conversion Efficiency

"In only a few short months since adding our new co-evaporation capability and control approach to our CIGS process development, we've achieved efficiencies of over 14 percent," said Chief Technology Officer, XsunX, Inc., Robert G. Wendt. "This efficiency level and the efficiency distribution is a significant achievement. In addition to achieving high efficiency levels, we demonstrated excellent cell voltage in the range of 620 to 660 millivolt (mV) clearly demonstrating the incorporation of gallium near the junction in the cell structure which is necessary for producing high efficiencies. We are working hard to further improve on this rapid success so that we can deliver the best possible CIGS technology to the market."



Deposition of the CIGS cell layers was conducted on full size 125 mm square substrates. Test configurations used to


Initial Production Results 1st Transportable Enhanced Oil Recovery Platform, PDGO Oil Stock News

The T-EOR Platform, a new and innovative industry oil production system, is a turnkey integrated and portable oil recovery platform that can be deployed quickly and economically to recover oil from previously producing oil wells with known oil reserves that have not been fully developed. The company has identified over 6,000 abandoned wells in the State of Texas alone that are potential oil producing candidates for the T-EOR Platform.....


Positive Phase 3 Study Results for the Treatment of Cushings Syndrome, Results for CORLUX : CORT

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive top-line results from its Phase 3 study of CORLUX for the treatment of Cushing's Syndrome. The study evaluated the response of two patient groups to CORLUX treatment: one included patients who were glucose intolerant and one included patients who were hypertensive. Statistically significant improvement in the primary endpoint was achieved for both groups: with 60% responding in the glucose intolerant group and 43% in the hypertensive group. An initial review of safety data indicates that CORLUX was well tolerated by Cushing's Syndrome patients in this Phase 3 study. "The results of the study demonstrate that CORLUX has the potential to become an important treatment option for patients suffering from Cushing's Syndrome," said Joseph Belanoff, M.D., Chief Executive Officer of Corcept. "We remain on track to submit a New Drug Application (NDA) to the FDA for CORLUX in Cushing's Syndrome by the end of the first quarter of 2011 and continue to work toward our goal of making CORLUX available to patients with this severe disease."


Wednesday, December 22, 2010

1st Transportable Enhanced Oil Recovery Platform Production Implementation, Oil Stock News PDGO

has completed its testing and has approved for Oil production field use, its first Transportable Enhanced Oil Recovery (T-EOR) Platform. The company announced it took delivery of the first T-EOR Platform on September 29, 2010. The T-EOR Platform is now on route to the company's Chilson A and B properties for its first field use.



The T-EOR Platform, a new and innovative industry oil production system, is a turnkey integrated and portable oil recovery platform that can be deployed quickly and economically to recover oil from previously producing oil wells with known oil reserves that have not been fully developed. The company has identified over 6,000 abandoned wells in the State of Texas alone that are potential oil producing candidates for the T-EOR Platform.


Saturday, December 18, 2010

SIRI Stock News, Stock News SIRI Investors Social Network

Please refer to this post to find up to date news for SIRI stock.


EVCARCO Alternative Fuel and Electric Car Dealership Franchise Into Hawaii, EVCA Electric Car

Electric Cars are coming to a state near you!.... EVCARCO's strategy of expansion through franchising will aid in establishing EVCARCO as pioneers of the automotive industry's newest segment of alternative fuel vehicle sales and distribution.



EVCARCO completed its Federal Disclosure Documents (FDD) and is now currently eligible to franchise in Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Nebraska, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, West Virginia, and Wyoming.

Fronteer Gold Enters Agreement Sell Uranium Assets to Paladin Energy, FRG Gold Stock

Under the terms of the Agreement, Fronteer Gold will receive 52.1 million common shares of Paladin valued at C$260.87 million, calculated using the recent five-day volume weighted average price of Paladin common shares on the TSX. Upon closing, Fronteer Gold will be the largest Paladin shareholder at approximately 6.7%. Closing of the transaction is expected in the first quarter 2011 and remains subject to applicable regulatory approvals, including approval of the TSX.


NX Global Inc Announces Growth in Its Subsidiary NUBE Inc, NEGS Stock News Cloud Computing

With the focus on the Cloud Computing and Virtualization, the company has changed its name from Global Green Resources, Inc to NUBE, Inc. NUBE is a Latin word for CLOUD. The name change speaks to our clarification in direction and solidifies our growth into Latin America.



Training and Boot-camps -- We are poised to deliver virtualization training in a 2 week bootcamp format. Our classes are authorized by VMware and our VMware Authorized Training Center (VATC) partner, Arrow Electronics Inc (ECS). Arrow is one of the world's largest IT and electronic companies. We are proud to announce our schedule:


Friday, December 17, 2010

Vicals VaxfectinR Demonstrates Potential as Universal Adjuvant, VICL DNA-BASED Vaccines

Vicals (VICL) researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor.  The company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models. Vaxfectin®-formulated H5N1 influenza DNA vaccines were well-tolerated and elicited durable immune responses within the predicted protective range in initial human studies.

"Vaxfectin® has many of the desired features of a successful adjuvant," said Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, "including the ability to significantly improve immune responses and favor specific types of immune responses. With a promising safety profile in preclinical and initial clinical studies, ease of formulation, stability and low manufacturing costs, Vaxfectin® is well-positioned as a potential 'universal' adjuvant for either immune enhancement or dose sparing applications in a broad range of infectious disease and cancer vaccines. A comprehensive new review of Vaxfectin® results published in the journal Expert Opinion on Drug Delivery[1] details Vaxfectin®'s development to date and should help us expand our outreach to potential licensees."

Vaxfectin® has been shown in multiple animal models to significantly increase the antibody and T-cell immune responses to antigens expressed from plasmid DNA vaccines. Results from two Phase 1 clinical trials of Vaxfectin®-formulated H5N1 influenza DNA vaccines demonstrated strong antibody responses and achieved T-cell responses in 75% to 100% of subjects in various dose cohorts. Vaxfectin® has demonstrated similar effect with protein-based vaccines, and the formulation can be adjusted to favor specific immune responses. The current publication reviews non-clinical immunological and efficacy studies of Vaxfectin® in several infectious disease and cancer models, preclinical safety and toxicology studies, clinical development of Vaxfectin®-formulated DNA vaccines, and studies of Vaxfectin®'s mechanism of action.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.

ACTC Markets Are Just Starting Appreciate Significance of Their Stem Cell, Derived Treatments Stem Cell Stock

"Stem Cells could and do currently provide enormous benitfit to a great many"....The condition destroys the pigmented layer of retina (retinal pigment epithelium) which is the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells. Advanced Cell Technology has shown success introducing the embryonic stem cell derived RPE cells into the eye in animal models and this resulted in 100% improvement with no side effects for more than 220 days. Human clinical trials are expected to start in the first quarter of 2011, and can potentially take only a few weeks to show positive results. ...


Advaxis India Cervix Cancer Trial Begins Dosing ADXS Cancer Stock

... The U.S. National Cancer Institute’s Gynecologic Oncology Group has conducted 16 clinical trials in over 500 patients using various therapeutic regimens in this patient population and found the most effective regimen tested resulted in a median survival of approximately 6 months and a 1 year survival of 5%. By contrast, in a phase 1 study not designed to show efficacy, ADXS11-001 demonstrate a median survival of 347 days and a one year survival of 53%. ...


Wednesday, December 15, 2010

VNDA Vanda Pharmaceuticals Receives Positive Ruling from the IRS

... "received a private letter ruling (PLR) from the Internal Revenue Service (IRS) regarding certain income tax issues associated with the availability of Vanda's net operating loss carryforwards for tax purposes. The PLR is generally consistent with Vanda's stated tax position that it is able to offset a portion of its 2010 taxable income with the company's full net operating loss carryforwards. Total net operating loss carryforwards were $123 million as of December 31, 2008. As of December 31, 2009, total net operating loss carryforwards were $156 million." ... Now that is worth a lot to somebody! Takeover potential?

Tuesday, December 14, 2010

Demonstrates a 300 kilowatt Fuel Cell DFC300 Power Plant US Army Base Ca

This project will demonstrate the high efficiency, reliability and ultra-clean benefits of a fuel cell power plant to the U.S. Army for a minimum of fourteen months. The project will involve the relocation and installation of a DFC300 power plant owned by the DoD that was operated at another military base under a one year demonstration program. The Camp Parks project represents the first Direct FuelCell® (DFC®) fuel cell power plant on a U.S. Army base following fuel cell power plant installations at U.S. Navy, Air Force and Marine bases.



The U.S. military is the largest single consumer of energy in the USA, using 79 percent of the total energy consumed by the Federal Government in 2006. The DoD energy policy includes improving energy efficiency, expanding use of renewable and ultra-clean energy and reducing green house gas emissions, while reducing the risk to the military and critical national infrastructure from losses of power. The high efficiency and ultra-clean attributes of fuel cells that dependably generate power at the point of use make fuel cell power plants well suited for powering U.S. military bases.....


Apple and the Christmas effect AAPL could rake it in this season

I would not be surprised to hear about "record" iTune sales this season. It wouldn't surprise me either if the entire product line of Apple does better than expected. Tizz the Season. Now what does that mean to the common share price? Time will tell. AAPL almost traded at $300 level twice. Is that a support level? Are we in a trading range? Is it better to stay in this range for a while than POW!



What are your thoughts?

VLNC Future Car Challenge Valence TechnologyPowered eVito Taxi Takes Home a Win, Lithium Battery Producer

“As the first company to design a powertrain for a fully homologated electric vehicle, we were excited to take part in the Future Car Challenge to help promote a low carbon future,” stated Zytek Automotive managing director, Neil Heslington, who drove the eVito. “In the Challenge, we not only finished with range to spare but won our class, so we have a lot to celebrate.”

Monday, December 13, 2010

VNLC Future Car Challenge Valence TechnologyPowered eVito Taxi Takes Home a Win

Nov. 19, 2010 (Business Wire) -- Valence Technology, Inc. (NASDAQ: VLNC), a leading U.S.-based manufacturer of advanced energy storage solutions, announced today that the Mercedes Electric Vito (eVito) Taxi – a seven-seat electric vehicle powered by Valence batteries – was awarded Most Economic & Environment Friendly Multi-Purpose Electric Vehicle at the Royal Automobile Club’s (RAC) Future Car Challenge. Held in the United Kingdom earlier this month, the Future Car Challenge drew a crowd estimated at more than 250,000.

The class-winning Zytek Mercedes eVito taxi, powered by Valence batteries.

Ascent Solar Announces Completion of Public Offering of Common Stock

Ascent Solar Technologies, Inc. (NASDAQ: ASTI) today announced that it has closed its previously announced public offering of 5.25 million shares of common stock at a price of $4.15 per share.

Ascent Solar received net proceeds, after offering expenses and underwriting discounts and commissions, of approximately $20.25 million. Ascent Solar expects to use the net proceeds from the offering for the completion of its FAB2 production plant and for general corporate purposes.

Cowen and Company, LLC acted as the sole book-running manager and Rodman & Renshaw, LLC and ThinkEquity LLC acted as co-managers in the offering. The offering was made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission.

PWAV Innovation Network Company Becomes Part of Revolutionary Model, Powerwave Technologies Joins

a global leader in end-to-end wireless coverage and capacity solutions, announces that it has joined the EDGE Innovation Network, a collaborative, open-environment initiative enabling industry and academia, with government input, to work together to enhance the delivery cycle of new technologies and innovative capabilities to warfighters and first responders....


Powerful HighEfficiency MultiString Backlight LED Drivers Optimized for, Notebooks, Netbooks, Monitors and Portab

Advanced Analogic Technologies, Inc. (AnalogicTech™) (Nasdaq: AATI), an analog semiconductor company focused on powering innovative solutions in consumer, industrial, and communications markets, today introduced its AAT1409/7/5 family of multi-string LED backlight drivers. Offering integrated boost converters and precision current sinks that can support up to 88 LEDs at 360mA total LED current, the AAT1409/7/5 drivers are among the most powerful in the marketplace. These new drivers bring to market a fully featured solution that reduces the number of backlight PCBs, reducing costs, yet is capable of driving high brightness LEDs and ensuring uniformity across the display by precisely controlling the backlight intensity.


NKTR Significant Efficacy in ThirdLine Treatment Metastatic Breast Cancer

"These are important new results for NKTR-102 in patients with metastatic breast cancer," said Prof. Ahmad Awada, Head of the Medical Oncology Clinic at the Institut Jules Bordet in Brussels, Belgium. "The high confirmed objective response rate continues to show that NKTR-102 is one of the most active single agents in this disease. This is particularly evident given the number of patients with dramatic reduction in lung and liver metastases." ....



"NKTR-102 is quickly emerging as a very important potential new drug in the fight against cancer," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer. "The drug has consistently high response rates as a single-agent in multiple Phase 1 and 2 clinical studies to-date, including our study in platinum-resistant ovarian cancer and now in metastatic breast cancer. This clinical benefit we've observed in tumor settings, where a highly active topoisomerase 1 inhibitor could be extremely useful, makes us very excited about the future of NKTR-102." .....

Friday, December 10, 2010

RNIN Wireless Ronin Announces Purchase Order RoninCastR for Automotive

"We are pleased with the reemergence of the automotive industry and the role we see RoninCast for Automotive playing in this marketplace," said Scott Koller, president and chief operating officer of Wireless Ronin Technologies, Inc. "This demonstrates the automotive industry's forward thinking approach to the in-dealership customer experience using RoninCast digital signage software. We believe this further solidifies our position in the automotive industry and we seek to continue to strengthen this position as we build on these relationships."


SWIR Sierra Wireless modules to transmit clinical data in real time to

The Dyna-Vision™ is a multi-purpose remote patient monitoring device used by cardiologists, general practitioners and health centers all over the world. About the size of a PDA and carried by the patient on a belt, the unit is connected to non-invasive sensors attached to the skin which measure up to twelve clinical parameters, including heart rate, respiratory rate, temperature, plethysmogram (changes in volume within an organ), SpO2 (the patient's oxygen saturation level) and skin temperature. The latest feature of Dyna-Vision™ is to accurately predict critical medical conditions of patients, such as cardiac arrest, up to six hours before they occur. By early intervention by medical staff, it is now possible to prevent the patient's condition from deteriorating. This feature helps healthcare providers reduce complications, patient injuries and length of hospital stays.


RVSN RADVISIONs SCOPIA Mobile Version 2 Delivers Advanced Conferencing

... "a leading technology and end-to-end solution provider for unified visual communications including video network infrastructure, developer tools and high definition (HD) room, desktop and mobile video conferencing systems, today announced the availability of SCOPIA Mobile V2, the first conferencing application for the Apple® iPhone® and iPad™ that allows users to participate in video conferences with standards-based audio and H.239 data collaboration" ....


OPCO United States Court of Appeals Rules in Favor of OurPets Company

... United States Court of Appeals for the Federal Circuit ("Court") issued its decision in favor of OurPet's Company and its SmartScoop™ Self Scooping Litter Box. The Court's decision reverses the ITC Commission's determination of a violation under section 337 of the Tariff Act of 1930 and vacated the corresponding exclusion orders and cease and desist orders previously issued in favor of Applica Consumer Products, Inc. ("Applica") in 2009. ...


Thursday, December 9, 2010

PWER PowerOne Launches Dedicated Central Solar Inverter for Asian Market

... "This product offers high performance with affordable capital expenditure and has been specifically designed for the fast growing Asian market," said Paolo Casini, Power-One's Vice President for Marketing. "Its design is the result of the experience we have acquired with more than 50MW of installation in the challenging Asian market."



Power-One is currently the world's second largest manufacturer of solar power inverters. With manufacturing centers in three continents, Power-One and its Aurora brand of solar and wind power inverters, ranging from 2kw to 2.5MW, offer best-in-class product performance and reliability along with a global customer care package. ...


WBSI Stock News WebSafety Announces Coverage by Harbinger Research

... Brian R. Connell, CFA, a Harbinger Research Senior Analyst, stated, "We are thrilled to have a company such as WebSafety under research coverage, as we believe its shares hold ...


Wednesday, December 8, 2010

TSLA Tesla Roadster Owner in Germany Logs 65000 km in One Year, Tesla Electric Car EV

"As soon as I started driving my Tesla Roadster, the petrol in my blood turned electric," von Gemmingen said. "When I was driving a conventional car, I did not look for outlets, so I didn't understand how easy it would be to charge an EV. But now I see outlets everywhere, and I don't have problems charging at home or on the road."


EMKR Solar EMCORE Enters Agreement Establish Its Suncore Joint Venture in China

..."China is viewed as one of the most promising markets for CPV solar power," said Dr. Hong Q. Hou, President and CEO of EMCORE. "This Agreement demonstrates Huainan's strategy and commitment to the growth of its renewable energy industry. These financial incentives will accelerate the commercialization of EMCORE's CPV technology and production ramp. We believe that this investment by Huainan and the establishment of Suncore's low cost manufacturing operation, will enable our CPV technology to become a cost effective solution for commercial and power utility applications," added Dr. Hou. ...

Tuesday, December 7, 2010

SOPK Stock News New Line of Interactive Educational Games 4 Nintendo DS, Mobile Apps

SouthPeak Interactive Corporation develops and publishes interactive entertainment software for all current hardware platforms including: Xbox 360® videogame and entertainment system from Microsoft, PlayStation®3 computer entertainment system, PSP® (PlayStation® Portable) system, PlayStation®2 computer entertainment system, Wii™, Nintendo DS™, iPhone and Windows PC. SouthPeak's games cover all major genres including action/adventure, role-playing, strategy, racing, puzzle, sports and edutainment. SouthPeak's products are sold in retail outlets in North America, South and Central America, Europe, Australia and Asia. SouthPeak is headquartered in Midlothian, Virginia, and has offices in Grapevine, Texas and Leicester, England.



SouthPeak’s extensive portfolio of over 60 interactive entertainment games spans a variety of platforms and genres including RPG, simulation, FPS, sports, strategy, puzzle and fighting.


Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma, SPPI Stem Cell Stock

Prior to stem cell transplantation to a patient, the existing disease must be eradicated. Therefore, patients undergo conditioning regimens to eliminate, in the case of blood cancers, all or most of the tumor cells. This also destroys the patient’s blood generating (hematopoietic) system. Following conditioning, stem cells either derived from the patient’s own system (autologous) or from a matched donor (allogeneic) are introduced to the patient to renew the hematopoietic system.



“These data solidify the role of ZEVALIN in treatment regimens for lymphoma patients,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. “These presentations confirm our belief that ZEVALIN will continue to show strong data in a range of protocols to prepare lymphoma patients for these life-saving procedures.”


Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma

Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma: "Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma, SPPI Stem Cell Stock"

Prior to stem cell transplantation to a patient, the existing disease must be eradicated. Therefore, patients undergo conditioning regimens to eliminate, in the case of blood cancers, all or most of the tumor cells. This also destroys the patient’s blood generating (hematopoietic) system. Following conditioning, stem cells either derived from the patient’s own system (autologous) or from a matched donor (allogeneic) are introduced to the patient to renew the hematopoietic system. 

“These data solidify the role of ZEVALIN in treatment regimens for lymphoma patients,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. “These presentations confirm our belief that ZEVALIN will continue to show strong data in a range of protocols to prepare lymphoma patients for these life-saving procedures.” 

Ajay K. Gopal, MD, Assistant Professor of Medical Oncology at the University of Washington School of Medicine and an Assistant Member of the Clinical Research Division of the Fred Hutchinson Cancer Research Center, presented data on the use of ZEVALIN, Fludarabine, and TBI based Non-Myeloablative Allogenic Transplant Conditioning for High-Risk B-Cell lymphomas (n=40). Non-myeloablative allogeneic transplantation (NMAT) can provide prolonged remissions in patients with advanced B-cell lymphoma via the graft versus lymphoma effect, though patients and donors need to be carefully selected. Dr. Gopal’s data indicated that use of ZEVALIN in NMAT is safe and feasible, and can lead to early objective responses and prolonged disease control in a subset of patients. 

Dr. Gopal’s ASH presentation is entitled Y-90 Ibritumomab Tiuxetan, Fludarabine, and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma. ASH Abstract #33. 

Monday, December 6, 2010

PCYG Park City Group Announces Significant SaaS Customer Win

... “Park City Group is increasingly becoming the technology partner of choice for the retail supply chain,” said Ken Aull, Exec VP – IT for Bunzl Distribution USA, Inc. “Following a formal review of vendors, Park City Group was selected because it has the most comprehensive solution covering hosted VMI and demand planning services among other important features. With a strong reputation for customer service and sophisticated software solutions, Park City Group will help us ensure that our retail trading partners have the products they need to maximize their revenue opportunities and manage their inventory and working capital. Bunzl’s goal is to be positioned starting in 2011 to offer VMI services to key customers as an additional value-add to the breadth of existing information based value-add services that we provide our customers, as a means of differentiating ourselves from our competitors.”...


QLTS Q Lotus Holdings Inc Enters Into Agreement to Acquire IRIS

This just sounds so cool :

"IRIS conducts advanced research in the area of imaging and scanning technologies and working with Radiological Ventures was responsible for completing Phase I and Phase II of the Department of the Navy's small bore scanner at the Navy's Explosive Ordinance Depot. The initial award was for $1.095 Million of which $425,000 remains upon completion of Phase III. "

I want to play with that stuff.


Saturday, December 4, 2010

FBCD Stock news Super Rad Industries to Acquire Mobile Application Company

..."Having mobile and gaming applications to either stand independently or act in concert with our toy or merchandise releases, is an important part of the modern day toy industry," said Christopher LeClerc, CEO of Super Rad Industries. LeClerc continues, "Having the ability to bring mobile applications and games along with toy releases is an exciting part of the business and where we believe the future lies." ....


Thursday, December 2, 2010

SLW Silver Wheaton Reports Record Quarterly Earnings, Trading near the 52 week high!

SLW ... Net earnings more than doubled to a record US$69.2 million (US$0.20

per share), compared with US$33.6 million (US$0.11 per share) in

2009.... This is one solid earning report. Check out the rest of the INFO!


WAVX Stock News Wave Introduces Wave BitLocker Manager for Windows 7

Interest in data protection has been growing as the incidents of data breach have escalated. Legislation in many jurisdictions now requires tough penalties, as well as public disclosure, when personally identifiable information is mishandled.

That's led many SMBs and enterprises to explore implementing full disk encryption. With the much-publicized launch of Microsoft Windows 7 operating system (OS), many are examining the full disk encryption feature that comes standard on Ultimate and Enterprise editions of the popular new OS. By providing full-volume encryption, BitLocker ensures that any file saved on a computer's drive is encrypted automatically.


Wednesday, December 1, 2010

MFTH Medisafe 1 Technologies Locking Syringe Adds ERP Compatibility

"Customizing our syringe locking device to work with ERP systems, enables a hospital to keep more accurate records, and eliminates additional possibilities for human error in the administration of medications via syringe," said, Jacob Elhadad, CEO of Medisafe 1 Technologies.

"The combination of the system's simple locking device with state of the art record tracking works to protect hospitals and their patients. We are confident that hospitals will recognize the value of our patented system."


WellTek Subsidiary Unveils Platform for Integrating Network Marketing With

"Until now, social network users have had no way to leverage their personal network as a direct income opportunity. Today, we've changed that," said David George, CEO of WellCity. "We are the first social network to offer actual money to its users. With the integration of WellCity Market, our WellCity 'residents' have an unprecedented opportunity to help others achieve optimal health, while they earn income from the purchases made by their network of family and friends or 'neighbors.' It's a simple idea: users get paid every time their 'neighbors' make a purchase inside WellCity Market."


ZBB Stock News ZBB Energy Reiterates Strong and Growing Backlog

Insiders Accumulate Significant Ownership Positions in ZBB Energy


Keryx Biopharmaceuticals Announces Highly Statistically Significant

KERX : announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. In this study, conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA), Zerenex met the study's primary endpoint, described below, demonstrating a...


OmniVision Starts Mass Production of UltraCompact OV6930 Medical Image

..."Additionally, our advanced pixel design and proven manufacturing process keep our products affordable, allowing medical devices to be made disposable while increasing patient safety, operating room hygiene and ease-of-use for medical practitioners."...


OVTI OmniVision Launches Feature Rich 8 Megapixel RAW CMOS Image Sensor for the

One of the advanced features of the OV8820 is an integrated scaler, which enables EIS and maintains full FOV with improved signal-to-noise performance in 1080p HD video mode operating at 30 fps. Another key image processing feature is a 2 x 2 binning functionality with a post-binning re-sampling filter function that minimizes spatial artifacts and removes image artifacts around edges to deliver clean, crisp color images. This is...


Ocean Power Technologies Expands Relationship with Mitsui Engineering

Ocean Power Technologies, Inc. (Nasdaq: OPTT and London Stock Exchange AIM: OPT) ("OPT" or the "Company") is pleased to announce that it has expanded its relationship with Mitsui Engineering & Shipbuilding Co. Ltd. (“MES”) with the signing of a new contract to develop OPT’s PowerBuoy technology for its application in Japanese sea conditions. ......